| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.9 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0022 | 1 |
| mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | -0.0036 | 1 |
| mRNA | necrostatin-7 | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |